NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the predicted drugs, dasatinib (DB01254), a selective tyrosine kinase receptor inhibitor for treatment of chronic myelogenous leukemia, was reported to induce live dysfunction [52].